Invezz.com - “GLP-1 drugs don’t just change what people eat,” Karthik Srinivasan, communications strategy consultant, tells ...
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are signi ...
Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback